Bionexus Gene Lab Corp (BGLC)

$2.35 -0.14 (-5.69%)
Market Cap 5.55M
Revenue (ttm) 9.51M
Net Income (ttm) -1.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16.82%
Debt to Equity Ratio 0.00
Volume 2,600
Avg Vol 24,420
Day's Range N/A - N/A
Shares Out 2.36M
Stochastic %K 25%
Beta 5.17
Analysts Strong Buy
Price Target N/A

Company Profile

BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SH...

Industry: Specialty Chemicals
Sector: Basic Materials
Phone: 60 1 307 241 6898
Address:
Menara UOA Bangsar, Unit A-28-7, Level 28, Tower A No.5 Jln Bangsar Utama 1, Kuala Lumpur, Malaysia
TheBigSauce
TheBigSauce Mar. 27 at 11:20 AM
$AEHL $BGLC $NWGL $RETO $VMAR NWGL šŸ‘€Volume. Ready for big bounce AEHL Iā€™ll be on bid again
0 Ā· Reply
TheBigSauce
TheBigSauce Mar. 26 at 8:14 PM
$AEHL šŸšØšŸ“ˆ Short cover time? Reminds me of $TIRX $LGHL and $BGLC before their big runs
0 Ā· Reply
TheBigSauce
TheBigSauce Mar. 25 at 11:17 PM
$NWGL šŸšØ Top oversold play. This can easily double imo. Loading the boat again. $BGLC and $RETO šŸ‡ØšŸ‡³ You know the game. Load bottoms and wait for the spike. Over and over $VMAR šŸš¤ Its the TSLA of the seas $AEHL šŸ‘€šŸŽIā€™ll be loading this one now
1 Ā· Reply
RebelXion
RebelXion Mar. 24 at 4:16 AM
$BGLC : BioNexus appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics. He will lead global commercialization of the VitaGuardā„¢ MRD platform (minimal residual disease testing in oncology). The company highlighted this as a step to expand in precision oncology.
0 Ā· Reply
Sulty
Sulty Mar. 17 at 7:31 PM
$BGLC Longs! Itā€™s time
0 Ā· Reply
aafetygod
aafetygod Feb. 28 at 6:50 AM
$BGLC 1.93 to 3.35... Hmm, even if it goes up, itā€™ll probably cap out at 3.5 or less. Itā€™s creeping up on low volume, so thereā€™s not much profit to be made unless you bought at the absolute bottom. Personally, Iā€™m hoping for a 50-60% drop.
1 Ā· Reply
FarhodKh
FarhodKh Feb. 27 at 4:23 PM
$BGLC This is not financial advice!!!
0 Ā· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 1:05 AM
$BGLC RSI: 56.60, MACD: -0.2269 Vol: 0.28, MA20: 2.34, MA50: 3.22 šŸŸ¢ BUY - Uptrend + healthy RSI šŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 Ā· Reply
Sulty
Sulty Feb. 24 at 8:26 PM
$BGLC Longs! Absolutely no Colin and we are up! Can yiu image what will happen when we pivot on positive news! Rocketing! Straight to 10$ easily
0 Ā· Reply
FlashTrigger
FlashTrigger Feb. 20 at 5:18 PM
$BGLC BioNexus Gene Lab operates diagnostics services. Revenue visibility is limited. Liquidity risk remains high.
0 Ā· Reply
Latest News on BGLC
BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuardā„¢ MRD Platform

Mar 11, 2026, 8:45 AM EDT - 18 days ago

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuardā„¢ MRD Platform

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

Feb 23, 2026, 8:30 AM EST - 4 weeks ago

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

BioNexus Launches Regional Deployment of VitaGuardā„¢ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market

Jan 28, 2026, 9:00 AM EST - 2 months ago

BioNexus Launches Regional Deployment of VitaGuardā„¢ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuardā„¢

Dec 3, 2025, 8:45 AM EST - 4 months ago

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuardā„¢

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

Dec 2, 2025, 8:05 AM EST - 4 months ago

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuardā„¢ MRD Platform as Part of Strategic Alliance with Tongshu Gene

Dec 1, 2025, 8:00 AM EST - 4 months ago

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuardā„¢ MRD Platform as Part of Strategic Alliance with Tongshu Gene

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

Nov 12, 2025, 8:00 AM EST - 4 months ago

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

Nov 10, 2025, 8:00 AM EST - 4 months ago

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

Oct 20, 2025, 8:00 AM EDT - 5 months ago

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Allianceā€”Touted as a new ā€œDeepSeek Momentā€ in Precision Oncology

Jul 30, 2025, 8:00 AM EDT - 8 months ago

BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Allianceā€”Touted as a new ā€œDeepSeek Momentā€ in Precision Oncology

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

Apr 30, 2025, 11:25 AM EDT - 11 months ago

BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

Apr 15, 2025, 11:00 AM EDT - 1 year ago

BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

Mar 7, 2025, 11:00 AM EST - 1 year ago

BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

Mar 5, 2025, 11:00 AM EST - 1 year ago

BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

Sep 25, 2024, 11:31 AM EDT - 1 year ago

BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd.

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

Sep 13, 2024, 12:05 PM EDT - 1 year ago

BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

Sep 12, 2024, 1:23 PM EDT - 1 year ago

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

Sep 11, 2024, 11:05 AM EDT - 1 year ago

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

Aug 27, 2024, 11:35 AM EDT - 1 year ago

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

Aug 26, 2024, 12:15 PM EDT - 1 year ago

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

Apr 18, 2024, 2:52 PM EDT - 2 years ago

BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

Jul 24, 2023, 11:30 AM EDT - 2 years ago

BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market

BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Jul 20, 2023, 1:29 PM EDT - 2 years ago

BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market

TheBigSauce
TheBigSauce Mar. 27 at 11:20 AM
$AEHL $BGLC $NWGL $RETO $VMAR NWGL šŸ‘€Volume. Ready for big bounce AEHL Iā€™ll be on bid again
0 Ā· Reply
TheBigSauce
TheBigSauce Mar. 26 at 8:14 PM
$AEHL šŸšØšŸ“ˆ Short cover time? Reminds me of $TIRX $LGHL and $BGLC before their big runs
0 Ā· Reply
TheBigSauce
TheBigSauce Mar. 25 at 11:17 PM
$NWGL šŸšØ Top oversold play. This can easily double imo. Loading the boat again. $BGLC and $RETO šŸ‡ØšŸ‡³ You know the game. Load bottoms and wait for the spike. Over and over $VMAR šŸš¤ Its the TSLA of the seas $AEHL šŸ‘€šŸŽIā€™ll be loading this one now
1 Ā· Reply
RebelXion
RebelXion Mar. 24 at 4:16 AM
$BGLC : BioNexus appointed Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics. He will lead global commercialization of the VitaGuardā„¢ MRD platform (minimal residual disease testing in oncology). The company highlighted this as a step to expand in precision oncology.
0 Ā· Reply
Sulty
Sulty Mar. 17 at 7:31 PM
$BGLC Longs! Itā€™s time
0 Ā· Reply
aafetygod
aafetygod Feb. 28 at 6:50 AM
$BGLC 1.93 to 3.35... Hmm, even if it goes up, itā€™ll probably cap out at 3.5 or less. Itā€™s creeping up on low volume, so thereā€™s not much profit to be made unless you bought at the absolute bottom. Personally, Iā€™m hoping for a 50-60% drop.
1 Ā· Reply
FarhodKh
FarhodKh Feb. 27 at 4:23 PM
$BGLC This is not financial advice!!!
0 Ā· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 26 at 1:05 AM
$BGLC RSI: 56.60, MACD: -0.2269 Vol: 0.28, MA20: 2.34, MA50: 3.22 šŸŸ¢ BUY - Uptrend + healthy RSI šŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 Ā· Reply
Sulty
Sulty Feb. 24 at 8:26 PM
$BGLC Longs! Absolutely no Colin and we are up! Can yiu image what will happen when we pivot on positive news! Rocketing! Straight to 10$ easily
0 Ā· Reply
FlashTrigger
FlashTrigger Feb. 20 at 5:18 PM
$BGLC BioNexus Gene Lab operates diagnostics services. Revenue visibility is limited. Liquidity risk remains high.
0 Ā· Reply
aafetygod
aafetygod Feb. 20 at 4:00 AM
$BGLC Personally, I'm hoping this stock drops below $1. It's going to hit 3āˆ’5 eventually anyway, so I might as well buy it cheap.
0 Ā· Reply
aafetygod
aafetygod Feb. 20 at 3:43 AM
$BGLC 3.5-5 Next week runner.
1 Ā· Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:12 AM
$BGLC Current Stock Price: $2.25
1 Ā· Reply
optionravi
optionravi Feb. 17 at 8:32 AM
$BGLC Obscure micro-cap; minimal information
0 Ā· Reply
TheBigSauce
TheBigSauce Feb. 16 at 10:41 PM
$NWGL šŸ‡ØšŸ‡³šŸš€Iā€™m a buyer here. This is my top China play now. Weā€™ve been banking China nicely in 2026 $JDZG Huge winner with $TIRX. $AURE and $BGLC also big wins
0 Ā· Reply
TheBigSauce
TheBigSauce Feb. 14 at 9:41 AM
$NWGL šŸ‡ØšŸ‡³ Another oversold China play expecting a bounce. Iā€™m a buyer. Also moved massive $TIRX prifits here. I see several joined me as well $LGHL and $HUDI two others to keep watch and $BGLC too. China New Year celebrations next week!
0 Ā· Reply
TheBigSauce
TheBigSauce Feb. 10 at 10:25 PM
$CHR šŸ™Loaded below $1.20. Today we saw $1.50. We arenā€™t done. Cash per share is $39 with buyout offers $26-28 $NWGL ā€¼ļø Loading more here. This will double. I feel another China bang bang coming $TIRX banked $AURE banked $BGLC banked. China has been good
0 Ā· Reply
ChartDiver
ChartDiver Feb. 9 at 12:17 PM
$BGLC is a biotech or digital health company; the name is not widely known, suggesting a very early-stage or stagnant public entity.
0 Ā· Reply
TheBigSauce
TheBigSauce Feb. 8 at 2:15 AM
$AURE $BGLC $LGHL $TIRX šŸ‘‡ šŸ‘€ šŸš€China has been our jam. We were first on TIRX and ither runners āœ…$CHR Next China bang bang! Low float. $39 cash/share. Buyout offers $26-28/share
0 Ā· Reply
trader87
trader87 Feb. 6 at 2:04 PM
$BTOG $FTFT $SQFT $BGLC who will make it first? gl folks!
0 Ā· Reply
TheBigSauce
TheBigSauce Feb. 6 at 11:07 AM
$NWGL šŸ‡ØšŸ‡³ Another oversold China play expecting a bounce. Iā€™m a buyer. Also moved massive $TIRX prifits here. I see several joined me as well $LGHL and $HUDI two others to keep watch and $BGLC too. Letā€™s see if todayā€™s market rebounds
0 Ā· Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 4 at 8:18 PM
$BGLC RSI: 18.78, MACD: -0.4007 Vol: 0.53, MA20: 3.24, MA50: 3.82 āšŖ HOLD - Sideways šŸ‘‰ https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 Ā· Reply